Study on the Effects of Serum Soluble Intercellular Adhesion Molecule-1 in Patients with Graves Disease Before and After Treatment

Objective:To evaluate the alteration and clinical significance of serum soluble intercellular adhesion molecule(sICAM-1) in patients with Graves disease(GD) in different periods.Methods:The levels of sICAM-1 of GD with untreated and treated were measured with two kinds of ELISA before and 3,6,12,18,24 and 30 months after the treatment of ATD,and were compared with the normal group.The correlation between sICAM-1 and FT3、FT4、sTSH were analyzed.Results:The serum sICAM-1 level in 116 health adults was(125.27±29.55) μg/L,and the positive ratio was 3.45%(4/116).The serum sICAM-1 level in 295 untreated GD was(236.68±72.74) μg/L,and the positive ratio was 75.59%(223/295),which was signifi-cantly higher than that of normal group(P 0.01).The positive ratios were 78.42%(149/190),63.01%(92/146),53.91%(62/115),30%(24/80),18.52%(10/54) and 13.64%(2/22) 3,6,12,18,24 and 30 months after the treatment respectively.There was no significant difference in level and positive ratio of serum sICAM-1 30 months after the treatment compared with that of normal group(P 0.05).There was no correlation between sICAM-1 and the thyreoid function(FT3、FT4、sTSH) either in untreated GD or treated GD(P 0.05).Conclusion:The serum sICAM-1 can reflect immunologic injury of GD.It can be used as an index in diagnosing,evaluating the therapeutic effects and the time to cease treatment in GD.